Publications

Peer-reviewed publications

Below is a list of selected publications by Dr. Heiser. For a complete listing, please see the compilation at Laura Heiser's NCBI Collection. Note: an asterisk (*) denotes equal contributions by multiple authors.

  1. Kimmel GJ, Dane M, Heiser LM, Alrock PM, Andor N. Integrating mathematical modeling with high throughput imaging explains how polyploid populations behave in nutrient-sparse environments. Cancer Res, 16 Sep 2020. doi.org/10.1158/0008-5472.CAN-20-1231

  2. Hunt GJ, Dane MA, Korkola JE, Heiser LM, Gagnon-Bartsch JA. Automatic Transformation and Integration to Improve Visualization and Discovery of Latent Effects in Imaging Data. Journal of Computational and Graphical Statistics, 25 Feb 2020. doi.org/10.1080/10618600.2020.1741379

  3. Gross et al., Individual Cells Can Resolve Variations in Stimulus Intensity along the IGF-PI3K-AKT Signaling Axis, Cell Systems (2019), https://doi.org/10.1016/j.cels.2019.11.005

  4. Bucher E, Claunch CJ, Hee D, Smith RL, Devlin K, Thompson W, Korkola JE, Heiser LM. Annot: a Django-based sample, reagent, and experiment metadata tracking system. BMC Bioinformatics. 2019 Nov 1;20(1):542. PMID: 31675914.

  5. Niepel M, Hafner M, Mills CE, Subramanian K, Williams EH, Chung M, Gaudio B, Barrette AM, Stern AD, Hu B, Korkola JE, LINCS Consortium, Gray JW, BirtwisBucher E, Claunch CJ, Hee D, Smith RL, Devlin K, Thompson W, Korkola JE, Heiser LM. Annot: a Django-based sample, reagent, and experiment metadata tracking system. BMC Bioinformatics. 2019 Nov 1;20(1):542. PMID: 31675914.tle MR*, Heiser LM*, Sorger PK*. A multi-center study on the reproducibility of drug response assays in mammalian cell lines. Cell Systems. 2019 Jul 24;9(1):35-48.e5. PMID: 31302153.
    Featured in The Scientist
    Featured in BioWorld

  6. Coleman DJ, Gao L, King CJ, Schwartzman J, Urrutia J, Sehrawat A, Tayou J, Balter A, Burchard J, Chiotti KE, Derrick DS, Sun D, Xia Z, Heiser LM*, Alumkal JJ*. BET bromodomain inhibition blocks the function of a critical AR-independent master regulator network in lethal prostate cancer. Oncogene. 2019 Apr 17. PMID: 30996246.

  7. Smith R, Devlin K, Kilburn D, Gross S, Sudar D, Bucher E, Nederlof M, Dane M, Gray J, Heiser LM, Korkola J. Using Microarrays to Interrogate Microenvironmental Impact on Cellular Phenotypes in Cancer. J Vis Exp. 2019 May 21;(147). PMID: 31180341

  8. Coleman J, Gao L, Schwartzman J, Korkola JE, Sampson D, Derrick DS, Urrutia J, Balter A, Burchard J, King CJ, Chiotti KE, Heiser LM, Alumkal JJ. Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancer. Scientific Reports 9, 3823 (2019). PMCID: PMC6405739.

  9. Sehrawat A, Gao L, Wang Y, Bankhead A, McWeeney SK, King CJ, Schwartzman J, Urrutia J, Bisson WH, Coleman DJ, Joshi SK, Kim D-H, Sampson DA, Weinmann S, Kallakury BVS, Berry DL, Haque R, Van Den Eeden SK, Sharma S, Bearss J, Beer TM, Thomas GV, Heiser LM, Alumkal JJ. LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. PNAS. 2018 Mar 26. PMCID: PMC5939079.
  10. Watson SS, Dane M, Chin K, Tatarova Z, Liu M, Liby T, Thompson W, Smith R, Nederlof N, Bucher E, Kilburn D, Whitman M, Sudar D, Mills GB, Heiser LM, Jonas O, Gray JW*, Korkola J*.Microenvironment Mediated Mechanisms of Resistance to HER2 Inhibitors Differ Between HER2+ Breast Cancer Subtypes. Cell Systems. 2018 Mar 14. PMCID: PMC5927625.
    • Featured on cover
  11. King C, Woodward J, Schwartzman J, Coleman D, Lisac R, Wang N, Van Hook K, Gao L, Urrutia J, Dane M, Heiser LM*, Alumkal JJ*. Integrative molecular network analysis identifies emergent enzalutamide resistance mechanisms in prostate cancer. Oncotarget. 2017; Nov 20;8(67):111084-111095. PMCID: PMC5762307.
  12. Hafner M*, Heiser LM*, Williams E, Niepel M, Wang N, Korkola J, Gray J, Sorger P. Quantification of sensitivity and resistance of breast cancer cell lines to anti-cancer drugs using GR metrics. Nature Scientific Data. 2017; Nov 7; 4:170166. PMCID: PMC5674849.
  13. Hassan S, Esch A, Liby T, Gray JW, Heiser LM. Pathway-enriched gene signature associated with 53BP1 response to PARP inhibition in triple-negative breast cancer. Molecular Cancer Therapeutics. 2017; Dec;16(12):2892-2901. PMCID: PMC5765867.
  14. Hill SM*, Heiser LM*, Cokelaer T, Unger M, Nesser NK, Carlin DE, Zhang Y, Sokolov A, Paull EO, Wong CK, Graim K, Bivol A, Wang H, Zhu F, Afsari B, Danilova LV, Favorov AV, Lee WS, Taylor D, Hu CW, Long BL, Noren DP, Bisberg AJ; HPN-DREAM Consortium, Mills GB, Gray JW, Kellen M, Norman T, Friend S, Qutub AA, Fertig EJ, Guan Y, Song M, Stuart JM, Spellman PT, Koeppl H, Stolovitzky G, Saez-Rodriguez J, Mukherjee S. Inferring causal molecular networks: empirical assessment through a community-based effort. Nature Methods. 2016 Apr; 13(4):310-8. PMCID: PMC4854847.
  15. Goodspeed A, Heiser LM, Gray JW, Costello JC. Tumor-derived cell lines as molecular models of cancer pharmacogenomics. Molecular Cancer Research. 2016 Jan;14(1):3-13. PMCID: PMC4828339.
  16. Costello JC*, Heiser LM*, Georgii E*, Gonen M, Menden MP, Wang NJ, Bansal M, Ammad-ud-din M, Hintsanen P, Khan SA, Mpindi J-P, NCI DREAM Community, Kallioniemi O, Honkela A, Aittokallio T, Wennerberg K, Collins JJ, Gallahan D, Singer D, Saez-Rodriguez J, Kaski S, Gray JW, Stolovitzky G. A community effort to assess drug sensitivity prediction algorithms identifies approaches for improved performance. Nature Biotechnology. 2014; 32(12):1202-12. PMCID: PMC4547623.
  17. Daemen A*, Griffith OL*, Heiser LM, Wang NJ, Enache OM, Sanborn Z, Pepin F, Durinck S, Korkola JE, Griffith M, Hur JS, Huh N, Chung J, Cope L, Fackler MJ, Umbricht C, Sukumar S, Seth P, Sukhatme VP, Jakkula LR, Lu Y, Mills GB, Cho RJ, Collisson EA, Van't Veer LJ, Spellman PT, Gray JW. Modeling precision treatment of breast cancer. Genome Biology. 2013 Oct21; 14(10):R110. PMCID: PMC3937590.
  18. Heiser LM, Sadanandam A, Kuo WL, Benz SC, Goldstein TC, Ng S, Gibb WJ, Wang NJ, Ziyad S, Tong F, Bayani N, Hu Z, Billig JI, Dueregger A, Lewis S, Jakkula L, Korkola JE, Durinck S, Pepin F, Guan Y, Purdom E, Neuvial P, Bengtsson H, Wood KW, Smith PG, Vassilev L, Hennessy BT, Greshock J, Bachman KE, Hardwicke MA, Park JW, Marton LJ, Wolf DM, Collisson EA, Neve RM, Mills GB, Speed TP, Feiler HS, Wooster RF, Haussler D, Stuart JM, Gray JW, Spellman PT.  Subtype and pathway specific responses to anti-cancer compounds in breast cancer. PNAS, 2012 Feb 21;109(8):2724-9. PMCID: PMC3286973.